SA
SAB Biotherapeutics, Inc.
SABSW · NASDAQ
$0.02 -0.55% (-$0.00)
1M -7.14%
Market Cap $174.0K
P/E Ratio -
Div. Yield -
ROE 6.74%
Bulios Fair Price
$0.03
64.8% upside
Current Price
$0.018
Undervalued Fair Value Overvalued
According to Bulios Fair Price, SABSW is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
100 /100
Cheap P/B 0.00x
PEG N/A
P/S N/A
Growth
100 /100
Growing Book val. growth 69.59%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor ROE 6.74%
ROA 5.36%
Asset turnover 0.00x
Debt
69 /100
Low Current ratio 9.22x
Int. coverage -54.18x
Debt/Equity 0.02x
Stability
32 /100
Unstable Rev. volatility 31.74%
EPS volatility 83.32%
Profitable years 1
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about SABSW
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Samuel J. Reich
Employees
86
Headquarters
Miami Beach
Upcoming events
17 NOV
Earnings
Upcoming earnings report